The DESTINY-Breast12 study confirmed T-DXd as a highly effective treatment for HER2-positive breast cancer, with BMs overcoming the blood–brain barrier, achieving a CNS-specific PFS of 58.9% and an ORR of 71.7%, which significantly improved patient outcomes [86]. The gene discussed is ERBB2; the disease is breast cancer.